ダブルT細胞とNK細胞による抵抗性腫瘍を標的とするワクチン
Soumya Badrinath1,2, Maxence O Dellacherie3,4, Aileen Li3,4,5
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nature
|May 25, 2022
まとめ
この新しいがんワクチンは MICA/Bタンパク質を標的にして 免疫細胞の攻撃を強化します 腫瘍の成長や転移を 効果的に阻害します
科学分野:
- 免疫学
- 腫瘍学
- ワクチン開発
背景:
- ペプチド抗原を標的とする従来のがんワクチンは,主要な組織適合性複合体 (MHC) の多様性のためにパーソナライズする必要があります.
- 腫瘍はしばしば,ペプチド表現を妨害し,MICA/Bストレスタンパク質を放出することによって,T細胞免疫を回避する.
- MICA/Bタンパク質は,自然キラー (NK) とT細胞NKG2D受容体のリガンドであり,免疫認識に不可欠である.
研究 の 目的:
- 免疫回避メカニズムを克服するためにMICA/Bストレスタンパク質を標的とした癌ワクチンを開発する.
- 調整されたT細胞とNK細胞の反応を誘発するワクチンの能力を調査する.
- MHCクラスI欠乏性腫瘍に対するワクチンの有効性を評価し,手術後の転移を予防する.
主な方法:
- MICA/Bストレスタンパク質を標的としたワクチンの開発
- MICA/Bの流出を抑制し,抗原のプレゼンテーションを高めるために抗体を誘導する.
- MHC欠乏した腫瘍および術後の設定を含む臨床前モデルでのワクチンの有効性の評価.
主要な成果:
- このワクチンは,脱落を阻害し,デンドリット細胞による抗原プレゼンテーションを増加させることで,MICA/ Bの表面密度を増加させます.
- 調整されたT細胞とNK細胞の攻撃を促進します.
- このワクチンはMHCクラスI欠乏性腫瘍に対する有効性を示し,手術後の転移を抑制します.
結論:
- このMICA/B標的のがんワクチンは,T細胞とNK細胞を巻き込んだ 強力で調整された免疫反応を誘発します.
- MHC欠乏症やMICA/Bの脱出を含む一般的な腫瘍免疫脱出メカニズムを克服します.
- このワクチンは,原発腫瘍の除去後に癌の再発と転移を予防する有望な効果を示しています.
さらに関連する動画
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.6K
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
1.1K
関連する概念動画
Tumor Immunotherapy
677
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cytotoxic T Cells-mediated Immune Response
2.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines
526
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
526
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
